xbrl.rienks.biz
English 
Nederlands
Français
Deutsch Crucell N.V.
| Address | Exchange | Stocks (07-10-2008: 16:07:00) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
-2.81%Industry: Health Care
Sector: Biotechnology
Companies engaged in research into and development of biological substances for the purposes of drug discovery and diagnostic development, and which derive the majority of their revenue from either the sale or licensing of these drugs and diagnostic tools.
| Crucell N.V. | (CRXL) | Biotechnology |
| Fornix BioSciences N.V. | (FORBI) | Biotechnology |
| Galapagos | (GLPGA) | Biotechnology |
| Pharming Group N.V. | (PHARM) | Biotechnology |
| English | Dutch | |
| Form20-F 2006 (3.33 MB) (Ernst & Young) Annual Report 2005 (4.24 MB) (Ernst & Young) Annual Report 2004 (0.82 MB) (Ernst & Young) Annual Report 2003 (4.57 MB) (Ernst & Young) | Jaarverslag 2005 (1.07 MB) (Ernst & Young) Jaarverslag 2004 (1.53 MB) (Ernst & Young) Jaarverslag 2003 (0.89 MB) (Ernst & Young) |
News
| Crucell wins NIAID/NIH contract for development of filovirus vaccine (07 Oct)
Netherlands-based biopharmaceutical company Crucell has received a National Institutes of Allergy and Infectious Diseases/National Institutes of Health contract aimed at advancing the development of a multivalent filovirus vaccine that includes both Ebola and Marburg viruses... Crucell gets $70 million US contract for vaccines (03 Oct)Dutch biotechnology company Crucell NV said Friday it received a contract worth up to $70 million from the National Institutes of Allergy and Infectious Diseases to develop a vaccine for both the Ebola and Marburg viruses... Crucell Receives NIAID/NIH Contract for Development of Ebola and Marburg Vaccines (03 Oct)Dutch biopharma company Crucell N.V. today announced that it received a National Institutes of Allergy and Infectious Diseases /National Institutes of Health contract aimed at advancing the development of a multivalent filovirus vaccine that includes both Ebola and Marburg viruses. The contract provides funding of up to $30 million, with additional options that may be triggered at the ..... | Crucell reports positive results from Phase II rabies study (03 Oct)
Biopharma company Crucell has announced positive preliminary results of the first Phase II clinical study of its investigational rabies monoclonal antibody combination, which started on March 31, 2008 in the US... Zacks #1 Rank Additions for Tuesday (07 Oct)Here are the stocks added to the Zacks #1 Rank List for Tuesday... Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US (01 Oct)Dutch biopharma company Crucell N.V. today announced the preliminary results of the first phase II clinical study of its investigational rabies monoclonal antibody combination, which started on 31 March 2008 in the US... |
Financial Calendar
| Yearly result | Quaterly Results | Analyst & Investor Conference |
|---|---|---|
| 13-02-2007 | Q1 - | - |
| Q2 - | - | |
| AGM | Q3 - | - |
| - | Q4 - | - |
Annual Accounts Crucell N.V.